Table 3 Viral titers at V1 and V2 (log[x + 1]) in respective groups
Population | Treatment | Number of virus events | Visit | Virus titer (median (25%; 75% percentile) | Significance (Wilcoxon Signed Rank Test) | Reduction in viral titers (difference V1-V2) (median (25%; 75% percentile) | Significant difference between carrageenan and placebo (Mann- Whitney U- test) |
|---|---|---|---|---|---|---|---|
ITT | Verum (n = 116) | 154 | V1 | 4.64 (3.41;6.57) | p = 0.022 | ||
Verum (n = 116) | 154 | V2 | 3.61 (0;4.97) | p < 0.001 | −2.2 (−3.47;-0.26) | ||
Placebo (n = 120) | 163 | V1 | 4.49 (3.24;6.3) | ||||
Placebo (n = 120) | 163 | V2 | 3.82 (0;4.85) | p < 0.001 | −1.14 (−3.31;0.31) | ||
PP | Verum (n = 87) | 115 | V1 | 4.66 (3.4;6.54) | p = 0.044 | ||
Verum (n = 87) | 115 | V2 | 3.63 (0;4.83) | p < 0.001 | −2.25 (−3.47;-0.57) | ||
Placebo (n = 87) | 113 | V1 | 4.99 (3.35;6.49) | ||||
Placebo (n = 87) | 113 | V2 | 3.98 (2.24;4.89) | p < 0.001 | −1.2 (−3.24;0.21) |